For Consumers
Tenth anniversary of the first protease inhibitor approval
This week marks the tenth anniversary of the approval of the first protease inhibitor. In December of 1995, a then new class of drug for the treatment of HIV/AIDS in combination with other antiretroviral drugs represented an historical landmark in the treatment of HIV/AIDS. Protease inhibitors helped establish a new treatment standard of triple combination therapy, significantly improving the lives and health of people living with HIV in the United States and around the world.
Richard Klein
HIV/AIDS Program Director
Office of Special Health Issues
Food and Drug Administration
Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration







